Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

PLTR

Palantir Technologies (PLTR)

Palantir Technologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:PLTR
DateTimeSourceHeadlineSymbolCompany
07/18/20133:00AMGlobeNewswire Inc.U.S. National Institutes of Health Recommend to Expand Its Scope of Research in the Development of Pluristem's PLX-RAD Cells foNYSE:PLTR
07/11/20132:00AMGlobeNewswire Inc.Pluristem Completes Enrollment for Phase I/II Muscle Injury TrialNYSE:PLTR
07/08/20132:00AMGlobeNewswire Inc.Pluristem's South Korean Partner Files IND With Korean FDA for PLX CellsNYSE:PLTR
06/26/20132:00AMGlobeNewswire Inc.Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and CommercializaNYSE:PLTR
06/20/20132:00AMGlobeNewswire Inc.Pluristem's Preclinical Results for Its PLX-RAD Cells Published in the Journal PLOS ONENYSE:PLTR
06/19/20138:00AMGlobeNewswire Inc.Pluristem Provides Update on Clinical Status of IC TrialsNYSE:PLTR
06/10/20132:00AMGlobeNewswire Inc.Pluristem to Deliver Two Presentations During Israel's Largest Biotech Conference: IATI-BioMedNYSE:PLTR
06/04/20138:00AMGlobeNewswire Inc.Pluristem to Receive Clinical-hold Notice From the U.S. FDANYSE:PLTR
05/29/20133:00AMGlobeNewswire Inc.Pluristem to Present at FDA SymposiumNYSE:PLTR
05/22/20134:30AMGlobeNewswire Inc.Pluristem Welcomes Parliamentary State Secretary of the German Federal Ministry for Environmental, Nature Conservation and NuclNYSE:PLTR
05/13/20132:30AMGlobeNewswire Inc.Preclinical Research Shows PLX Cells May be Effective in Treating PreeclampsiaNYSE:PLTR
05/07/20132:00AMGlobeNewswire Inc.Pluristem Develops PLX-RAD Cells for Use in HematologyNYSE:PLTR
04/30/20132:00AMGlobeNewswire Inc.Pluristem to Present at Needham Healthcare and Oppenheimer Israeli Investment Conferences in May 2013NYSE:PLTR
04/29/20132:00AMGlobeNewswire Inc.Third Party Research Study Demonstrates Pluristem's PLX-PAD Cells' Safety in Human Lung Models of Pulmonary HypertensionNYSE:PLTR
04/18/20132:00AMGlobeNewswire Inc.Pluristem Expands PLX Product Portfolio in Orthopedics and Sports MedicineNYSE:PLTR
04/11/20132:00AMGlobeNewswire Inc.United Therapeutics Receives Regulatory Approval to Commence Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary ArterialNYSE:PLTR
04/10/20131:00AMGlobeNewswire Inc.Pluristem Announces Scientific and Investment Conferences for April 2013NYSE:PLTR
03/20/20132:00AMGlobeNewswire Inc.Pluristem Reports on the Progress of Its Phase I/II Clinical Trial for the Treatment of Muscle InjuryNYSE:PLTR
02/21/20131:30AMGlobeNewswire Inc.Pluristem Receives FDA Orphan Drug Status Designation for Treatment of Aplastic AnemiaNYSE:PLTR
02/13/20136:56AMGlobeNewswire Inc.CORRECTING AND REPLACING -- Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell SummNYSE:PLTR
02/13/20132:00AMGlobeNewswire Inc.Pluristem CEO to Participate in Key Roundtable Discussion at the 8th Annual New York Stem Cell Summit '13NYSE:PLTR
01/30/20132:00AMGlobeNewswire Inc.Pluristem Takes Possession of and Moving Into New State-of-the-Art Manufacturing FacilityNYSE:PLTR
01/22/20137:00AMGlobeNewswire Inc.Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry ConferenceNYSE:PLTR
01/15/20133:00AMGlobeNewswire Inc.Pluristem Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to GermanyNYSE:PLTR
01/07/20136:00AMGlobeNewswire Inc.Pluristem's CEO Letter to ShareholdersNYSE:PLTR
12/27/20122:00AMGlobeNewswire Inc.Pluristem Initiates Final Validation of New Manufacturing FacilityNYSE:PLTR
12/12/20122:00AMGlobeNewswire Inc.Pluristem to Present at Oppenheimer 23rd Annual Healthcare ConferenceNYSE:PLTR
12/04/20122:00AMGlobeNewswire Inc.Pluristem Advances Its Intramuscular Hematology Program; Assembles Clinical Advisory Board of World Renowned Opinion LeadersNYSE:PLTR
11/21/20125:00AMGlobeNewswire Inc.Pluristem Reports Status of Orphan Drug Application for Aplastic AnemiaNYSE:PLTR
11/14/20126:00AMGlobeNewswire Inc.Pluristem to Initiate a Phase I/II Clinical Trial in Muscle InjuryNYSE:PLTR
 Showing the most relevant articles for your search:NYSE:PLTR